<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937754</url>
  </required_header>
  <id_info>
    <org_study_id>Neo-4085</org_study_id>
    <nct_id>NCT01937754</nct_id>
  </id_info>
  <brief_title>Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults</brief_title>
  <official_title>Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neogenis Laboratories</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neogenis Laboratories</source>
  <brief_summary>
    <textblock>
      Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy
      adults with clinical prehypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Systolic and Diastolic Blood Pressure Readings</measure>
    <time_frame>30 days</time_frame>
    <description>Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Functional Capacity</measure>
    <time_frame>30 days</time_frame>
    <description>Participant will take a six minute walk test at baseline and again after thirty days during the follow-up appointment. Achieved distances will be measured and recorded.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>30 days</time_frame>
    <description>Participants will fill out a standardized quality of life questionnaire at baseline and again after thirty days during the follow-up appointment. Summary component scores will be recorded and compared.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prehypertension</condition>
  <arm_group>
    <arm_group_label>Nitric Oxide supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nitric Oxide supplement</intervention_name>
    <description>Lozenge consisting of beetroot and 75 mg caffeine</description>
    <arm_group_label>Nitric Oxide supplement</arm_group_label>
    <other_name>Neo40 Daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same form factor and flavor as test lozenge but contains no active ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between the ages of 18 to 80 years

          -  Two blood pressure readings of &gt;/=135/80 mmHg at rest, thus representing
             prehypertension

          -  Informed consent

        Exclusion Criteria:

          -  Existence of any significant internal or cardiovascular disease;

          -  Current use of any antihypertensive medication.

          -  Inability to give informed consent, or fill out standard questionnaires or inability
             to follow up clinically.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst Schwarz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Medical Institute, Cedars Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Medical Institute</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neogenis Laboratories</investigator_affiliation>
    <investigator_full_name>Dr. Ernst Schwarz</investigator_full_name>
    <investigator_title>Attending Cardiologist, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prehypertension</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Functional Capacity</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

